Article

Neoadjuvant combo efficacious in high-risk prostate cancer

One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.

Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
1 expert in this video
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
4 experts in this video
Related Content
Study shows value of precision-based approaches in prostate cancer
May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke
The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
May 19th 2025

Patient selection for cytoreductive nephrectomy in 2025

Daniel D. Shapiro, MD, FACS E. Jason Abel, MD, FACS
"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Blurred interior of hospital - abstract medical background. | Image Credit: © jakkapan - stock.adobe.com
May 15th 2025

Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy

Professor Andreas Skolarikos Hannah Clarke
Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.
© 2025 MJH Life Sciences

All rights reserved.